Biodimension Technology
Overview
Biodimension Technology Private Limited is a deep-tech startup centered on the development of human tissue and organ models through biofabrication technologies. The company was established in 2021 by three founders, namely Manoj Kumar Sampath, Ranjith Kumar Velusamy, and Pradeep Arunachalam. Headquartered in Bengaluru, India, Biodimension focuses on providing an ethical, human-relevant alternative to animal testing in the pharmaceutical and cosmetic industries. The company has successfully raised funding that supports its mission to revolutionize healthcare testing methods.
Recent Developments
- October 2024: Biodimension Technology secured ₹1.21 crore in a funding round led by Campus Angels Network. The investment is aimed at enhancing their cleanroom facilities, ramping up product development, and expanding marketing efforts.
- March 2024: The company announced its commercial stage, having started earning revenues and providing services to a top FMCG company in India.
- March 2023: Biodimension was awarded a grant from PETA India for advancing animal-free methods in toxicology testing, highlighting their focus on human skin models made from real human cells.
- January 2023: The company proudly showcased their 3D biofabricated human tissues at Global Bio India 2023, aiming to promote cruelty-free testing methods in pharmaceuticals and cosmetics.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | Bengaluru, India |
| Founders | Manoj Kumar Sampath, Ranjith Kumar Velusamy, Pradeep Arunachalam |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Campus Angels Network |
| Industry | Biotechnology, Tissue Engineering |
| Number of Employees | Approximately 10 |
Early History
Biodimension Technology emerged from the shared vision of its founders who were concerned about the ethical implications of animal testing in drug and cosmetic research. Ranjith Kumar Velusamy, Manoj Kumar Sampath, and Pradeep Arunachalam, who met during their Master’s program in Biotechnology at VIT, founded the company in January 2021. It was incubated at the VIT Technology Business Incubator (TBI) with the aim to replace animal trials with engineered human tissues. Supported by a network of incubators and early grants, the company made significant strides in its initial years. By June 2023, Biodimension had relocated to Bengaluru to capitalize on a more vibrant deep-tech ecosystem.
Company Profile and Achievements
Biodimension Technology has positioned itself as a leader in biofabrication, developing human tissue models that serve as viable alternatives to traditional animal testing. Major achievements include:
- Biofabricated Human Tissues: These are developed as functional replicas of human tissues, used for screening drugs, cosmetics, and chemicals for safety and effectiveness.
- Product Launches: The company has launched skin epidermis tissue models for cosmetic testing, with future plans to extend applications to drug screening and clinical uses.
- Partnerships and Collaborations: Engaging with prominent FMCG companies in India and maintaining institutional ties with VIT, Biodimension has fortified its position in the non-animal testing market.
- Recognition: In 2022, Biodimension was named the Best Tissue Engineering Company in South Asia at the Biotechnology Awards.
Current Operations and Market Position
Currently, Biodimension Technology is actively engaged in the production and distribution of biofabricated human tissue models. The company leverages its state-of-the-art facilities to offer a reliable platform for drug and cosmetic testing. Biodimension’s innovative solutions provide significant ethical and practical advantages over animal models, which often fail to predict human biological outcomes accurately. With ongoing efforts to expand its market through strategic partnerships and an emphasis on innovation, the company is well-positioned to make a substantial impact in the biotech industry.
Conclusion
Biodimension Technology exemplifies the transition towards more ethical and effective testing solutions in the biotechnology field. With its advancements in biofabrication and commitment to reducing dependence on animal models, the company stands at the forefront of a significant shift in pharmaceutical and cosmetic testing methodologies. Bolstered by recent significant funding and growing recognition in the industry, Biodimension is poised for substantial growth and influence as it continues to refine its models and expand its reach, potentially redefining industry standards for safety and efficacy testing in the coming years.